HUE042771T2 - Janus-kináz (JAK) inhibitorainak adagolási rendje - Google Patents

Janus-kináz (JAK) inhibitorainak adagolási rendje

Info

Publication number
HUE042771T2
HUE042771T2 HUE13742573A HUE13742573A HUE042771T2 HU E042771 T2 HUE042771 T2 HU E042771T2 HU E13742573 A HUE13742573 A HU E13742573A HU E13742573 A HUE13742573 A HU E13742573A HU E042771 T2 HUE042771 T2 HU E042771T2
Authority
HU
Hungary
Prior art keywords
jak
inhibitors
dosage regimen
janus kinase
janus
Prior art date
Application number
HUE13742573A
Other languages
English (en)
Hungarian (hu)
Inventor
Andrea J Gonzales
Sallie B Cosgrove
Phyllis B Malpas
Michael Rolf Stegemann
Wendy Turner Collard
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE042771(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of HUE042771T2 publication Critical patent/HUE042771T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HUE13742573A 2012-07-20 2013-07-18 Janus-kináz (JAK) inhibitorainak adagolási rendje HUE042771T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25

Publications (1)

Publication Number Publication Date
HUE042771T2 true HUE042771T2 (hu) 2019-07-29

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13742573A HUE042771T2 (hu) 2012-07-20 2013-07-18 Janus-kináz (JAK) inhibitorainak adagolási rendje

Country Status (25)

Country Link
US (1) US9522151B2 (enExample)
EP (1) EP2874630B1 (enExample)
JP (2) JP6022063B2 (enExample)
KR (2) KR20150028299A (enExample)
CN (2) CN104470525A (enExample)
AU (1) AU2013292547B2 (enExample)
BR (1) BR112015000808A2 (enExample)
CA (1) CA2878867C (enExample)
CY (1) CY1121436T1 (enExample)
DK (1) DK2874630T3 (enExample)
ES (1) ES2707627T3 (enExample)
HK (2) HK1209314A1 (enExample)
HR (1) HRP20182088T1 (enExample)
HU (1) HUE042771T2 (enExample)
IN (1) IN2015DN00370A (enExample)
LT (1) LT2874630T (enExample)
MX (1) MX360857B (enExample)
NZ (1) NZ703152A (enExample)
PL (1) PL2874630T3 (enExample)
PT (1) PT2874630T (enExample)
RS (1) RS58242B1 (enExample)
SI (1) SI2874630T1 (enExample)
SM (1) SMT201900044T1 (enExample)
WO (1) WO2014015107A1 (enExample)
ZA (1) ZA201500134B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290421B1 (en) 2013-02-22 2019-01-02 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
WO2017143014A1 (en) * 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CN111499641B (zh) * 2019-01-30 2021-06-04 格格巫(珠海)生物科技有限公司 一种jak抑制剂及其制备方法
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
EP4263559A1 (en) 2020-12-18 2023-10-25 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
MX2023010835A (es) * 2021-03-16 2023-09-29 Hk Inno N Corp Nuevas sales de compuestos heterocíclicos como inhibidores de proteínas quinasas y sus usos.
CA3216017A1 (en) * 2021-04-22 2022-10-27 Shengjian Huang Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50087B (sr) * 1998-06-19 2009-01-22 Pfizer Products Inc., Pirolo (2,3-d) pirimidin jedinjenja
PT2384326E (pt) * 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina

Also Published As

Publication number Publication date
JP2017019816A (ja) 2017-01-26
HK1252083A1 (zh) 2019-05-17
CN108354938A (zh) 2018-08-03
AU2013292547B2 (en) 2017-05-04
CN104470525A (zh) 2015-03-25
RS58242B1 (sr) 2019-03-29
MX360857B (es) 2018-11-20
ZA201500134B (en) 2016-08-31
US9522151B2 (en) 2016-12-20
BR112015000808A2 (pt) 2017-06-27
EP2874630A1 (en) 2015-05-27
DK2874630T3 (en) 2019-01-28
KR20150028299A (ko) 2015-03-13
JP2015522620A (ja) 2015-08-06
IN2015DN00370A (enExample) 2015-06-12
SI2874630T1 (sl) 2019-04-30
CA2878867C (en) 2018-01-09
ES2707627T3 (es) 2019-04-04
AU2013292547A1 (en) 2015-01-22
EP2874630B1 (en) 2018-12-05
CA2878867A1 (en) 2014-01-23
JP6022063B2 (ja) 2016-11-09
SMT201900044T1 (it) 2019-02-28
US20150126535A1 (en) 2015-05-07
PT2874630T (pt) 2019-01-31
HK1209314A1 (en) 2016-04-01
PL2874630T3 (pl) 2019-04-30
MX2015000871A (es) 2015-05-07
LT2874630T (lt) 2019-02-11
KR20170034949A (ko) 2017-03-29
HRP20182088T1 (hr) 2019-02-08
NZ703152A (en) 2016-03-31
CY1121436T1 (el) 2020-05-29
WO2014015107A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
HUE042771T2 (hu) Janus-kináz (JAK) inhibitorainak adagolási rendje
IL265007B (en) Pyrazolopyrimidine compounds as kinase inhibitors
DK3321262T3 (da) Serin-/threoninkinasehæmmere
EP2822935A4 (en) INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK)
DK2710007T3 (da) Kinasehæmmere
IL227399A0 (en) New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
EP2731612A4 (en) BRUTON TYROSINE KINASE HEMMER
CO6970602A2 (es) Inhibidores de quinasa
BR112013029620A2 (pt) inibidores de tirosina quinase de bruton
HUE049345T2 (hu) Nyújtott hatóanyag-leadású dózisformák JAK1 inhibitorhoz
DK2903618T3 (da) Rho-kinase-inhibitorer
HUE071468T2 (hu) ATR kináz inhibitorként alkalmazható vegyületek
EP2858500A4 (en) BRUTON TYROSINE KINASE HEMMER
IL230561A0 (en) Inhibitors of bruton's tyrosine kinsae
DK2922526T3 (da) Fremstilling af semiplastiske farmaceutiske doseringsenheder
DK2917210T3 (da) Alk kinase-inhibitorer
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
BR112015005361A2 (pt) inibidores de tirosina quinase de bruton
EP2931281A4 (en) AMINOPYRIDE-CONTAINING MILK TYROSINE KINASE HEMMER
PL2634185T3 (pl) Inhibitory kinazy TYK2
HUE052291T2 (hu) Tropomiozinnal rokon kináz (TRK) inhibitorok
BR112014033056A2 (pt) inibidores da proteína quinase
EP2782579A4 (en) PYRAZINKINASEINHIBITOREN
BR112014029718A2 (pt) inibidores da proteína quinase
DK3076969T3 (da) Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer